Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2

Jacobson, 1996, Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity, Proc Natl Acad Sci USA, 93, 10405, 10.1073/pnas.93.19.10405

Blattman, 2003, Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo, Nat Med, 9, 540, 10.1038/nm866

Lalezari, 2000, Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial, HIV Clin Trials, 1, 1, 10.1310/T5FR-8JPX-0NEF-XDKD

Dybul, 2002, Pilot study of the effects of intermittent Interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection, J Infect Dis, 185, 61, 10.1086/338123

Martinez-Marino, 2004, Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection, J Clin Immunol, 24, 135, 10.1023/B:JOCI.0000019778.96564.26

Goujard, 2007, Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study, AIDS Res Hum Retroviruses, 23, 1105, 10.1089/aid.2007.0047

2009, Interleukin-2 therapy in patients with HIV infection., N Engl J Med, 361, 1548, 10.1056/NEJMoa0903175

Smith, 2007, Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial, PLoS Clin Trials, 2, e5, 10.1371/journal.pctr.0020005

Palmer, 2003, New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma, J Clin Microbiol, 41, 4531, 10.1128/JCM.41.10.4531-4536.2003

Finzi, 1997, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278, 1295, 10.1126/science.278.5341.1295

Saez-Cirion, 2007, HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype, Proc Natl Acad Sci USA, 104, 6776, 10.1073/pnas.0611244104

Kaufmann, 2004, Limited durability of viral control following treated acute HIV infection, PLoS Med, 1, 137, 10.1371/journal.pmed.0010036

Rosenberg, 2000, Immune control of HIV-1 after early treatment of acute infection, Nature, 407, 523, 10.1038/35035103